Patient Recruitment in the Pivotal Phase 2-Study HORIZON Completed |
| September 27, 2019 | September 2019 Bond Updates |
|
STOCKHOLM, Sept. 26, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the last patient has been included in the OP-106 HORIZON pivotal phase 2 clinical study evaluating melflufen with dexamethasone in patients with relapsed/refractory multiple myeloma... |
| View more at: https://www.prnewswire.com:443/news-releases/patient-recruitment-in-the-pivotal-phase-2-study-horizon-completed-300926147.html |
| Related News |
|